The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 19.29

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2007-2013

Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 178,161 70.2 69.9 70.5 90.2 89.5 90.9 77.8 77.4 78.1 59.8 59.3 60.3
1 Hodgkin Lymphoma 14,839 86.4 85.7 87.1 96.6 95.5 97.4 90.0 89.3 90.7 56.7 53.7 59.7
2 Non-Hodgkin lymphoma 159,174 69.1 68.8 69.4 88.5 87.7 89.3 76.2 75.8 76.6 60.4 59.9 61.0
2(a) Non-Hodgkin lymphoma, B-cell 147,279 69.4 69.1 69.8 89.2 88.2 90.0 76.9 76.5 77.3 61.0 60.4 61.5
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 8,130 68.6 67.4 69.7 88.7 87.6 89.6 39.3 36.9 41.7 18.0 14.5 21.8
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 131,742 69.6 69.3 70.0 91.3 89.4 93.0 78.4 78.0 78.8 61.4 60.8 61.9
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 31,636 79.1 78.4 79.8 - - - 87.1 86.3 87.9 73.6 72.4 74.6
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 27,738 82.1 81.3 82.8 - - - 90.0 89.1 90.8 76.7 75.5 77.9
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 90 51.2 37.2 63.6 - - - 63.4 42.0 78.7 41.7 23.8 58.7
2(a) 2.1.3. Mantle-cell lymphoma 3,808 57.9 55.7 60.1 - - - 68.8 65.8 71.5 49.1 45.8 52.3
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 2,893 81.6 79.0 83.8 - - - 88.8 85.8 91.2 77.2 73.5 80.5
2(a) 2.2.1. Lymphoplasmacytic lymphoma 1,314 77.4 73.5 80.8 - - - 84.1 79.1 87.9 73.4 67.8 78.2
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,579 85.1 81.6 88.0 - - - 92.7 88.7 95.3 80.4 75.2 84.6
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 34,173 62.3 61.6 62.9 89.6 86.2 92.2 71.9 71.1 72.7 52.4 51.3 53.4
2(a) 2.3.1. DLBCL, NOSc 33,713 62.1 61.4 62.8 90.1 86.6 92.6 71.8 70.9 72.6 52.4 51.3 53.4
2(a) 2.3.2. Intravascular large B-cell lymphoma 61 50.1 34.4 63.9 - - - 51.0 31.9 67.2 49.5 25.4 69.7
2(a) 2.3.3. Primary effusion lymphoma 51 22.0 9.2 38.2 - - - 19.6 6.7 37.4 - - -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 348 87.6 82.5 91.2 - - - 89.3 84.1 92.8 - - -
2(a) 2.4. Burkitt lymphoma/leukemia 2,244 62.5 60.2 64.6 91.2 88.1 93.5 58.5 55.6 61.4 39.9 34.4 45.3
2(a) 2.5. Marginal-zone lymphoma (MZL) 9,606 90.0 88.8 91.0 98.6 90.2 99.8 93.5 92.3 94.5 86.5 84.4 88.4
2(a) 2.5.1. Splenic MZL 841 84.4 79.6 88.1 - - - 84.5 78.6 88.8 84.1 76.3 89.5
2(a) 2.5.2. Extranodal MZL, MALTc type 5,861 94.5 93.0 95.7 97.8 85.5 99.7 96.2 94.8 97.2 92.6 89.6 94.7
2(a) 2.5.3. Nodal MZL 2,904 82.6 80.1 84.7 - - - 89.8 87.2 91.9 76.7 72.9 80.1
2(a) 2.6. Follicular lymphoma 17,820 87.7 86.9 88.4 97.4 81.9 99.7 92.2 91.5 92.9 81.5 79.9 83.0
2(a) 2.7. Hairy-cell leukemia 1,562 93.5 90.8 95.4 - - - 96.7 94.5 98.1 85.1 77.2 90.5
2(a) 2.8. Plasma cell neoplasms 31,780 49.5 48.7 50.2 - - - 62.2 61.1 63.3 39.5 38.5 40.6
2(a) 2.8.1. Plasmacytoma 1,954 68.2 65.2 71.0 - - - 78.2 74.8 81.3 54.8 49.6 59.7
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 29,826 48.3 47.5 49.0 - - - 60.8 59.7 61.9 38.8 37.7 39.8
2(a) 2.9. Heavy chain disease 28 70.4 43.2 86.3 - - - - - - - - -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 7,407 67.3 65.7 68.9 92.1 83.1 96.4 76.2 74.1 78.1 61.2 58.9 63.5
2(b) Non-Hodgkin lymphoma, T-cell 10,802 65.4 64.3 66.5 86.2 84.0 88.2 69.4 68.1 70.8 50.9 48.5 53.2
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 404 67.0 62.1 71.5 89.6 84.4 93.2 50.0 42.2 57.3 6.4 0.6 23.3
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 10,359 65.4 64.3 66.6 85.4 82.9 87.7 70.2 68.8 71.5 51.4 49.0 53.7
2(b) 2.1. Mycosis fungoides/Sezary syndrome 2,605 90.3 88.2 92.1 96.6 76.7 99.6 92.8 90.7 94.4 84.7 79.2 88.8
2(b) 2.1.1. Mycosis fungoides 2,525 91.9 89.8 93.6 96.6 76.7 99.6 93.8 91.7 95.3 87.5 81.7 91.5
2(b) 2.1.2. Sezary syndrome 80 37.6 22.5 52.7 - - - 40.6 19.5 60.8 34.5 14.2 56.0
2(b) 2.2. Peripheral T-cell lymphoma 5,693 57.5 55.9 59.1 83.5 78.0 87.7 66.0 64.0 67.8 42.5 39.7 45.3
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 1,993 38.5 35.8 41.1 60.3 42.7 74.0 48.5 44.9 51.9 25.8 21.9 29.8
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 749 40.7 36.4 45.0 - - - 52.1 45.6 58.1 31.7 25.9 37.6
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 74 89.2 76.1 95.4 - - - 86.3 70.5 94.0 - - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 1,122 62.1 58.7 65.4 86.9 80.1 91.5 67.6 63.5 71.3 34.0 26.4 41.7
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 53 20.8 9.2 35.6 - - - 18.1 5.8 35.8 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 64 10.7 3.5 22.5 - - - - - - 15.9 4.3 34.1
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 1,126 84.4 81.1 87.2 96.3 76.3 99.5 88.2 84.6 90.9 77.5 71.2 82.5
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 512 89.3 84.1 92.8 - - - 94.6 90.0 97.1 78.7 65.5 87.3
2(b) 2.3. Adult T-cell leukemia/lymphoma 1,359 63.6 60.5 66.5 85.2 81.9 87.9 46.1 40.7 51.4 18.6 10.6 28.4
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 458 43.6 38.1 48.9 - - - 44.4 38.3 50.4 37.5 25.7 49.2
2(b) 2.5. T-cell large granular lymphocytic leukemia 78 70.4 56.5 80.6 - - - 78.9 61.9 89.0 57.0 34.4 74.4
2(b) 2.6. Prolymphocytic leukemia, T-cell 166 16.2 9.1 25.1 - - - 21.0 11.8 31.9 9.2 1.8 24.1
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 39 42.7 26.6 57.8 - - - - - - - - -
2(c) Non-Hodgkin lymphoma, unknown lineage 1,093 59.9 56.5 63.1 86.3 81.2 90.1 58.3 52.8 63.3 45.8 40.3 51.2
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 445 64.5 59.7 69.0 86.4 81.3 90.2 44.7 35.0 53.8 22.9 13.5 33.9
2(c) 2. Prolymphocytic leukemia, unknown lineage 39 50.3 33.2 65.2 - - - - - - 41.5 22.7 59.4
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 609 57.0 52.2 61.5 - - - 64.5 57.8 70.4 50.8 44.3 56.9
2(*) 1. Total precursor lymphoma/leukemiad 8,979 68.4 67.3 69.5 88.6 87.6 89.6 40.6 38.4 42.7 18.3 15.1 21.8
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 148 72.5 62.3 80.4 - - - 81.8 70.4 89.2 52.5 32.0 69.5
4 Lymphoid neoplasm, NOSc 4,000 50.2 48.3 52.2 85.2 75.4 91.3 63.5 60.6 66.1 40.1 37.3 42.8

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.